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PPIs target characterization:  
Structural and target interface information 
Protein surface flexibility analysis 
(Normal Mode Analysis (NMA))	  
Virtual Fragment-based screening and druggability 
CrystalDock  
Ligand-Protein pharmacophore hypothesis 
ZINCPharmer 	  
Re-docking hit-compounds  
AutoDock Vina in UCSF Chimera (Flexible) 
Energy minimization (UCSF chimera)  
ADME-tox (FAF-drug3) 
a
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c
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Figure 3 | Four comparisons of how a protein interacts with its natural protein 
(or peptide) partner and with a synthetic small molecule. The structures of 
protein–protein or protein–peptide complexes are shown on the left. The 
target protein is rendered as a filled surface (grey), and the binding protein or 
peptide is represented as a ribbon diagram (yellow), with selected side chains 
shown as sticks (with carbon in yellow, oxygen in red and nitrogen in blue). 
The contact surface on the target protein (within 4.5 Å of the binding partner) 
is shown in green. The structures of the protein–small-molecule complexes 
are shown on the right. The small molecule is shown in stick format, and 
the contact surface is shown in orange. In the centre, small molecules are 
shown superimposed on the protein in the conformation in which it binds to 
its natural protein or peptide partner, and the contact surface (on the target 
protein) of the natural interaction is shown in green. From these examples, 
it is clear that the protein–protein contact surface is much larger and flatter 
than the protein–small-molecule contact surface. a, IL-2 bound to its natural 
protein partner IL-2Rα (left), and IL-2 bound to the small molecule SP4206 
(right). b, Bcl-XL bound to a peptide derived from one of its natural protein 
partners, BAD, and Bcl-XL bound to the small molecule ABT-737. c, HDM2 
bound to a peptide derived from its natural protein partner p53, and HDM2 
bound to the small molecule Nutlin-2 (upper) or a benzodiazepinedione 
(lower). d, HPV-18 E2 bound to HPV-18 E1, and HPV-11 E2 bound to 
the small molecule compound 18. The centre panel is not shown, because 
HPV-18 and HPV-11 are related but not identical. Images generated from 
files from the PDB, as indicated in Table 1.
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FIGURE 2: IL-2Rα bound to the small molecule SP4206. The 
green surface on the left represents the IL-2 interaction with 
the receptor, while on the right the orange represents the small 
molecule contact surface (2).  
FIGURE 1: The drug discovery and development cascade and CADD role (1). 
FIGURE 5: Normal mode analysis applying elastic network modes with UCSF chimera.  
Mode 6: 0.95 Hz. Arrows show the positive displacement. 
FIGURE 3: Computational hit discovery strategy to 
inhibit VEGFR-D2 domain interaction with VEGF (3).  
FIGURE 4: Jagged1 structure and interaction surface in the N-terminal domain definition (PDB ID: 4CC0.A) (4).  
FIGURE 6: Fragments docked with CrystalDock along the DSL motif (RMSD < 2Å).  
FIGURE 7: Pharmacophore identification from the docked 
fragments interacting with the surface pocket using the 
ZINCPharmer online interface. 
 
(Up-Left) Global pharmacophore definition for 
the DSL motif. (Up/Bottom-right) An example of 
possible pharmacophore hypothesis for future 
research screening with ZINC database. 
 
Hydrophobic (H: green), Hydrogen bond donor 
(HBD: grey), Hydrogen bond acceptor (HBA: 
orange).  
Methodology followed to define the protocol: 
 
1.  Definition of the system to use as a proof of concept.  
2.  Intensive bibliographic search for computational drug discovery examples in PPIs. 
3.  Identification of key steps required for the cascades and search for free-software 
or webservers to apply a strategy like the one presented in figure 3. 
4.  Test the different programs and webservers in this proof of concept system to test 
their function in protein-protein interactions and choose the more suitable for the 
propose of the project. 
 
Selection of Jagged1-Notch interaction as a case of study: 
 
Notch signalling is a cell-cell communication system involved in cell proliferation, cell 
death, differentiation, among other functions. Jagged1 is the most characterised 
Notch-ligand in terms of structure and functions. The solved structures have a 
maximum resolution of 2.38 Å (PDB ID: 4CC0) and the interaction surface has been 
described. In addition, Jagged1-Notch interaction is a relevant therapeutic target 
to develop novel cancer treatments due to its role in tumour progression and cancer 
cells microenvironment control.  
PPIs target characterization	   Protein surface flexibility analysis	  
Ligand-protein pharmacophore hypothesis Virtual Fragment-based screening and druggability	  
Protein-protein interactions (PPIs) have a crucial role in cell signalling transduction 
and the execution of cellular functions, offering new therapeutic opportunities to treat 
pathologies such as transplant rejection (i.e. IL2/IL-2Rα) or cancer (i.e. Bcl-2/BAK).  
 
PPIs have singular features and different chemical spaces from conventional targets 
(i.e. enzymes), for this reason targeting PPIs with small molecules can be challenging 
(Figure 2). The main druggability challenges for PPIs are: 
•  Large interaction surface (1500-3000 Å2) 
•  Surface flatness: lack of grooves and cavities. 
•  Flexibility: surfaces are plastic and conformational changes.  
•  Electrostatic and solvent exposition. 
The presence of small regions in the interaction surface called hotspots (600 Å2) that 
confer most of the binding energy offers a key druggability advantage. 
Ø  Define a simple computational approach using free and user-friendly software compatible with the computer power of a regular laptop in 
order to target PPIs based on the current knowledge on computational development of PPIs’ inhibitors.  
Ø  Proof of concept for the first functional steps in the protocol using Jagged1-ligand and Notch-receptor interaction. 
Computational-aided drug discovery (CADD) is the implementation of computer technologies in the drug development cycle (Figure 1). Its role is mainly to improve and accelerate the hit 
discovery process, while it reduces the high costs associated with experimental methods. CADD also plays an important role in lead optimization and drug rational design. A widely used method in 
computational hit discovery is the structure-based approach, which is the implemented strategy in protein-protein interactions drug discovery. 
 
Structure-based drug discovery relies on the knowledge of proteins structures and explicit modelling of both chemicals and biological entities. The standard computational approach is 
molecular dockings. This methods sample ligand conformations from virtual compound libraries (chemicals or fragments) to dock them within the binding site of the biological structure and using 
scoring functions (simplified energetic functions) to predicted binding affinities. Among many strategies is the pharmacophore-based screening, in which pharmacophore hypothesis defines the 
virtual 3D arrangement of ligand's key physicochemical proprieties for the interaction with its biological target. These features are used as a scaffold or map to screen compounds libraries.  
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•  Target PPIs should have previous structural information and the interaction 
regions characterized to not add complexity and lose reliability. 
•  Hotspots and their druggability can be computationally characterised using webservers 
like DoGsitescorer or Fpocket, docking chemical probes or docking both proteins.  
•  The interaction surface of Jagged1 has been experimentally (residues mutagenesis) 
and computationally (proteins docking) defined in the N-terminal region (figure 4). The 
DSL motif has been postulated to be a relevant hotspot, where mutations in its 
residues led to the loss of function. 
PPIs surface are dynamic and flexibility assessment is crucial to study target 
pocket motion and its impact on druggability.  
 
Normal Modes Analysis determines the different modes of vibration of protein 
structures, where each mode correspond to atoms vibrating in a specific frequency, 
describing with several modes protein flexibility. The low-frequency modes provide 
information about proteins global motion.  
 
These calculations can be performed using the UCSF Chimera platform or webservers 
like FlexServ, DFprot or ElNémo. The NMA calculations show considerable motion 
along Jagged1 structure. The DSL motif remains apparently stable, but residues 
flanking the groove like Lys198 and Glu228 are rearranged when the pocket is 
deformed for the global movement. This could have implications in druggability.   
The fragment-based screening provides a more versatile screening for PPIs as it is 
based on docking small chemical fragments, covering wider chemical spaces than 
using small molecules. The application of CrystalDock offers an alternative approach 
for fragment-based screening to conventional free tools like DOCK or AutoDock. 
CrystalDock calculations show docked fragments along the DSL motif groove and in the 
associate subpocket 3, which have significant polar features (figure 6). These results 
might confirm motif’s druggability, but it could be affected by the relevant polar 
interactions of Glu228 in subpockets 1 and 2. 
Ø  Drug discovery in PPIs is currently an evolving field with a promising future for their notorious implications in human diseases and druggable potential. Although several computational screenings strategies have been reported to trigger PPIs, there is still not a defined 
procedure better than the others. It is probably a consequence of the PPIs singularity, challenging features and their still not completely clear chemical space.  
Ø  A simplified computational strategy to target PPIs using free and user-friendly software is proposed. The most important steps (pocket characterisation, druggability, flexibility, fragment-based docking and pharmacophore generation) have been successfully tested 
in the case of study (Jagged1). The tested steps set up the protocol’s base and provide confidence of its working possibilities. However, future validations and the full implementation of the protocol has to be preformed.  
Ø  The last steps proposed in the protocol are a crucial validation phase. The re-docking step using AutoDock Vina followed by the energy minimization of ligand-protein interaction will prove the proper binding interaction of selected hits from the pharmacophore screening 
and discard possible steric clashed. Finally, an ADME-tox filtering step with FAF-drug3 webserver is suggested to discard potential toxic compounds and select final hits with more optimal pharmacokinetic features.  
Ø  Although real concerns on Jagged1 druggability exist, the strategy here reported applied in Jagged 1 could represent the first step for a future drug discovery research campaign to identify novel compounds triggering Notch/Jagged1 signaling in cancer.  
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2) Subpockets identification with Surflex 
Druggability assessment with LigBuilder 
3) Receptor flexibility analysis 
using DFprot server (NMA) 
4) Docking of 8.0000 chemicals compounds from CERMN 
library with Surflex without flexibility 
5) Re-docking with Surflex considering flexibility 
(Complemented with specific docking using Autodock 4) 
1) VEGFR D2 structure solved with X-ray and NMR 
Interaction surface with VEGF defined 
6) Filter compound with free ADME software 
package  (FAF-Drugs2) / Medicinal chemist analysis  
